INTRODUCTION AND OBJECTIVES:
The androgen receptor (AR) pathway continues to drive castration-resistant prostate cancer (CRPC) even in late stages of the disease. While the latest generation anti-androgens provide clinical benefits to CRPC patients, resistance linked with the ligand binding domain (LBD) inevitably emerges. Selective inhibition of the N-terminal domain (NTD) of the AR can inhibit AR transcription even in the presence of anti-androgen resistance. A Phase I clinical trial of the first generation AR NTD inhibitor, EPI-506 (EPI-002 pro-drug), demonstrated PSA declines in anti-androgen resistant metastatic CRPC patients. However, these declines were minor and of short duration, revealing the need for more potent and metabolically stable NTD inhibitors. Next generation NTD inhibitors (anitens) have been developed and their characterization will be presented.
METHODS: Chemical structure activity relationships were developed in order to increase molecule potency in cellular and in vivo assays, while metabolic stability improvements were assessed in in vitro ADME assays and in animal pharmacokinetic studies. In addition, the on-target activity and selectivity was also optimized using a variety of cellular experiments.
RESULTS: Next generation anitens, EPI-7170, EPI-7245 and EPI-7324, demonstrated a 10-70 fold improvement on ARdriven cellular potency when compared to the clinical compound EPI-002. While IC50s ranged from <500 nM and w1 uM, for EPI-7245 and EPI-7170 respectively, EPI-7324 diplayed potency <300 nM, similar to enzalutamide and bicalutamide. In vitro proliferation assays demonstrated on-target activity for these next-generation anitens, with an IC50 >5 fold higher in AR-independent PC-3 cells compared to AR-dependant LNCaP cells while also displaying activity in AR-V7-driven cellular models. While EPI-7170 exhibited w 70% tumor growth inhibition in castrated mice bearing LNCaP tumors, its ADME and PK profile were not optimal. More recent molecules, including EPI-7245 and EPI-7324, represent next generation aniten molecules with improved potency, selectivity, and metabolic stability compared to EPI-002 and EPI-7170.
CONCLUSIONS: The next generation aniten compounds are 10-70 times more active than EPI-002 in cellular potency assays, predicted to be metabolically stable, and selectively inhibit AR transcription in anti-androgen resistant models. Their potential in INTRODUCTION AND OBJECTIVES: Emerging evidence supports that androgen receptor (AR) signaling regulates DNA repair in prostate cancer. Therefore, a combination approach using AR modulating drugs with radiation could be a promising option for the treatment of metastatic castration resistant prostate cancer (mCRPC). All currently approved AR modulating drugs, such as enzalutamide (ENZA) and abiraterone, either directly or indirectly target the AR C-terminus ligand-binding domain (LBD). Such drugs are often unsuccessful due to the emergence of AR splice variants (e.g., AR-V7) that are constitutively active and lack a LBD. EPI-002 is a first-in-class AR antagonist that binds to its N-terminus domain to inhibit the transcriptional activities of both full-length AR and AR splice variants. A next generation compound, EPI-7170 has been developed. Here we present data to support that a combination of EPI compounds and ionizing radiation maybe beneficial for the treatment of mCRPC.
METHODS: Androgen-independent LNCaP95 cells that are resistant to ENZA and endogenously express both full-length AR and AR-V7 were used. The effect of EPI compounds on the expression of DNA repair genes was measured using TaqMan array and Western blot analysis. Monotherapies versus combination therapies using EPI-002, EPI-7170, or ENZA, with ionizing radiation were evaluated for effects on proliferation, colony formation, cell cycle and DNA damage using BrdU incorporation, FACS and Western blot and immune fluorescent staining.
RESULTS: EPI-7170 was more potent than EPI-002. Both EPI-002 and EPI-7170 decreased expression of DNA repair genes contrary to ENZA. EPI-002 induced G1 cell cycle arrest whereas radiation induced G2/M cell cycle arrest. FACS analysis revealed a dosedependent decrease of BrdU incorporation with increased accumulation of gammaH2AX with combination therapy. A synergistic inhibitory effect on proliferation of ENZA-resistant LNCaP95 cells was achieved with a combination of EPI compounds with ionizing radiation.
CONCLUSIONS: Combination therapy with radiation and an antagonist to the AR NTD such as EPI-002 or EPI-7170 that inhibits the transcriptional activities of both AR-Vs and full-length AR, may provide a new therapeutic approach for mCRPC.
Source of Funding: US National Cancer Institute (R01 CA105304) awarded to MDS

MP34-06 INFLUENCE OF DIFFERENT MODALITIES OF ANDROGEN DEPRIVATION THERAPY ON LIPID AND GLUCOSE METABOLISM AND FAT ACCUMULATION IN PATIENTS WITH PROSTATE CANCER: DEGARELIX VS LEUPROLIDE PLUS BICALUTAMIDE
Harutake Sawazaki*, Daiji Araki, Higashimurayama, Japan INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) has a negative impact on lipid and glucose metabolism. In a mouse model, degarelix generated the least atherosclerosis and characteristics of metabolic syndrome (MS) compared with orchiectomy and leuprolide at week 16. FSH levels were significantly lower in degarelix than in orchiectomized and leuprolide-treated mice. The difference of FSH levels was associated with the extent of MS and atherosclerosis. We investigated the effects of different ADT modalities (degarelix, leuprolide) on development of MS in patients with prostate cancer.
METHODS: Patients with hormonal-naive prostate cancer were recruited between 2016 and 2018. Patients were randomized to receive treatment with either degarelix or leuprolide with bicalutamide for six months. Key trial variables monitored monthly were body weight, abdominal circumference and blood testing associated with lipid and glucose metabolism. CT was performed to measure areas of subcutaneous and visceral fat before and after 6 months of ADT.
RESULTS: Of 100 patients registered, 85 patients completed the trial (degarelix: 40 patients, leuprolide: 45 patients). Mean increases in body weight after degarelix and leuprolide were 1.1% and 1.5%, respectively. Mean increases in abdominal circumference after degarelix and leuprolide were 1.6% and 1.9%, respectively. There was no significant difference in lipid (total, LDL, HDL cholesterol and triglycerides) and glucose (fasting blood suger, HbA1c)metabolism between degarelix and leuprolide-treated patients. There was no significant difference in subcutaneous and visceral fat accumulation between degarelix and leuprolide-treated patients. FSH levels were significantly lower in degarelix than in leuprolide-treated patients (P<0.05).
CONCLUSIONS: FSH levels were lower in degarelix, but there was no significant difference in lipid and glucose metabolism between degarelix and leuprolide-treated patients. 
